Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > December report

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Dec 02, 2021 11:06am

148 Views

Post# 34189993

RE:RE:RE:December report

Wanbang has invested north of $5M USD on their end, so it will be interesting where this goes next. It is possibly evident from the IP registration that Wanbang may be in the bed with Elanco, Boehringer and Sirona on the pet side. Sounds juicy but only if they agree on the next step.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario